)
Summary of Presentation:
- Treatment with TSND-201 resulted in rapid and robust improvements in PTSD symptoms
- Placebo-adjusted CAPS-5 improvement of -9.64 points on Day 64 (p=0.012)
- Durable efficacy following an acute episodic dosing regimen (once per week for 4-weeks)
- TSND-201 was generally safe and well tolerated, with a safety profile consistent with its non-hallucinogenic pharmacology
